Genedrive (GDR.L) Stock Price

Genedrive Price

LSE·CLOSED
0.01GBP+0.0005 (+4.26 %)
Market closed

Over the last 19 years Genedrive grew revenue by 0.3% annually, reaching 954,000.00 GBP. Earnings per share have grown at 107.7% per year over the last 2 years. For Genedrive, the net margin of -548.3% is down versus -100.6% a few years ago. The consensus 12-month price target for Genedrive is 86.70 GBP, about 722,400.0% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 481% above its 52-week low.

Genedrive stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genedrive over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genedrive stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genedrive's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genedrive Stock Price History
DateGenedrive Price
8/6/20260.01 GBP
8/5/20260.01 GBP
8/4/20260.01 GBP
7/31/20260.01 GBP
7/30/20260.01 GBP
7/29/20260.01 GBP
7/28/20260.01 GBP
7/27/20260.01 GBP
7/24/20260.01 GBP
7/23/20260.01 GBP
7/22/20260.01 GBP
7/21/20260.01 GBP
7/20/20260.01 GBP
7/17/20260.01 GBP
7/16/20260.01 GBP
7/15/20260.01 GBP
7/14/20260.01 GBP
7/13/20260.01 GBP
7/10/20260.01 GBP
7/9/20260.01 GBP
7/8/20260.01 GBP
7/7/20260.01 GBP
7/6/20260.01 GBP
7/3/20260.01 GBP
7/2/20260.01 GBP
7/1/20260.01 GBP
6/30/20260.01 GBP
6/29/20260.01 GBP
6/26/20260.01 GBP
6/25/20260.01 GBP
6/24/20260.01 GBP
6/23/20260.01 GBP
6/22/20260.01 GBP
6/19/20260.01 GBP
6/18/20260.01 GBP
6/17/20260.01 GBP
6/16/20260.01 GBP
6/15/20260.01 GBP
6/12/20260.01 GBP
6/11/20260.01 GBP
6/10/20260.01 GBP
6/9/20260.01 GBP
6/8/20260.01 GBP
6/5/20260.01 GBP
6/4/20260.01 GBP
6/3/20260.01 GBP
6/2/20260.01 GBP
6/1/20260.01 GBP
5/29/20260.01 GBP
5/28/20260.01 GBP
5/27/20260.01 GBP
5/26/20260.01 GBP
5/22/20260.01 GBP
5/21/20260.01 GBP
5/20/20260.01 GBP
5/19/20260.01 GBP
5/18/20260.01 GBP
5/15/20260.01 GBP
5/14/20260.01 GBP
5/13/20260.01 GBP
5/12/20260.01 GBP
5/11/20260.01 GBP
5/8/20260.01 GBP
5/7/20260.01 GBP
5/6/20260.01 GBP
5/5/20260.01 GBP
5/1/20260.01 GBP
4/30/20260.01 GBP
4/29/20260.01 GBP
4/28/20260.01 GBP
4/27/20260.01 GBP
4/24/20260.01 GBP
4/23/20260.01 GBP
4/22/20260.01 GBP
4/21/20260.01 GBP
4/20/20260.01 GBP
4/17/20260.01 GBP
4/16/20260.01 GBP
4/15/20260.01 GBP
4/14/20260.01 GBP
4/13/20260.01 GBP
4/10/20260.01 GBP
4/9/20260.01 GBP
4/8/20260.01 GBP
4/7/20260.01 GBP
4/2/20260.01 GBP
4/1/20260.01 GBP
3/31/20260.01 GBP
3/30/20260.01 GBP
3/27/20260.01 GBP
3/26/20260.01 GBP
3/25/20260.01 GBP
3/24/20260.01 GBP
3/23/20260.01 GBP
3/20/20260.01 GBP
3/19/20260.01 GBP
3/18/20260.01 GBP
3/17/20260.01 GBP
3/16/20260.01 GBP
3/13/20260.01 GBP
3/12/20260.01 GBP
3/11/20260.01 GBP
3/10/20260.01 GBP
3/9/20260.01 GBP
3/6/20260.01 GBP
3/5/20260.01 GBP
3/4/20260.01 GBP
3/3/20260.01 GBP
3/2/20260.01 GBP
2/27/20260.01 GBP
2/26/20260.01 GBP
2/25/20260.01 GBP
2/24/20260.01 GBP
2/23/20260.01 GBP
2/20/20260.01 GBP
2/19/20260.01 GBP
2/18/20260.01 GBP
2/17/20260.01 GBP
2/16/20260.01 GBP
2/13/20260.01 GBP
2/12/20260.01 GBP
2/11/20260.01 GBP
2/10/20260.01 GBP
2/9/20260.01 GBP
2/6/20260.01 GBP
2/5/20260.01 GBP
2/4/20260.01 GBP
2/3/20260.01 GBP
2/2/20260.01 GBP
1/30/20260.01 GBP
1/29/20260.01 GBP
1/28/20260.01 GBP
1/27/20260.01 GBP
1/26/20260.01 GBP
1/23/20260.01 GBP
1/22/20260.01 GBP
1/21/20260.01 GBP
1/20/20260.01 GBP
1/19/20260.01 GBP
1/16/20260.01 GBP
1/15/20260.01 GBP
1/14/20260.01 GBP
1/13/20260.01 GBP
1/12/20260.01 GBP
1/9/20260.01 GBP
1/8/20260.01 GBP
1/7/20260.01 GBP
1/6/20260.01 GBP
1/5/20260.01 GBP
1/2/20260.01 GBP
12/31/20250.01 GBP
12/30/20250.01 GBP
12/29/20250.01 GBP
12/24/20250.01 GBP
12/23/20250.01 GBP
12/22/20250.01 GBP
12/19/20250.01 GBP
12/18/20250.01 GBP
12/17/20250.01 GBP
12/16/20250.01 GBP
12/15/20250.01 GBP
12/12/20250.01 GBP
12/11/20250.01 GBP
12/10/20250.01 GBP
12/9/20250.01 GBP
12/8/20250.01 GBP
12/5/20250.01 GBP
12/4/20250.01 GBP
12/3/20250.01 GBP
12/2/20250.01 GBP
12/1/20250.01 GBP
11/28/20250.01 GBP
11/27/20250.01 GBP
11/26/20250.01 GBP
11/25/20250.01 GBP
11/24/20250.01 GBP
11/21/20250.01 GBP
11/20/20250.01 GBP
11/19/20250.01 GBP
11/18/20250.01 GBP
11/17/20250.01 GBP
11/14/20250.01 GBP
11/13/20250.01 GBP
11/12/20250.01 GBP
11/11/20250.01 GBP
11/10/20250.01 GBP
11/7/20250.01 GBP
11/6/20250.01 GBP
11/5/20250.01 GBP
11/4/20250.01 GBP
11/3/20250.01 GBP
10/31/20250.01 GBP
10/30/20250.01 GBP
10/29/20250.01 GBP
10/28/20250.01 GBP
10/27/20250.00 GBP
10/24/20250.00 GBP
10/23/20250.01 GBP
10/22/20250.00 GBP
10/21/20250.01 GBP
10/20/20250.01 GBP
10/17/20250.01 GBP
10/16/20250.01 GBP
10/15/20250.00 GBP
10/14/20250.00 GBP
10/13/20250.00 GBP
10/10/20250.00 GBP
10/9/20250.00 GBP
10/8/20250.00 GBP
10/7/20250.00 GBP
10/6/20250.00 GBP
10/3/20250.00 GBP
10/2/20250.00 GBP
10/1/20250.00 GBP
9/30/20250.00 GBP
9/29/20250.00 GBP
9/26/20250.00 GBP
9/25/20250.00 GBP
9/24/20250.00 GBP
9/23/20250.00 GBP
9/22/20250.00 GBP
9/19/20250.00 GBP
9/18/20250.00 GBP
9/17/20250.00 GBP
9/16/20250.00 GBP
9/15/20250.00 GBP
9/12/20250.00 GBP
9/11/20250.00 GBP
9/10/20250.00 GBP
9/9/20250.00 GBP
9/8/20250.00 GBP
9/5/20250.00 GBP
9/4/20250.00 GBP
9/3/20250.00 GBP
9/2/20250.00 GBP
9/1/20250.00 GBP
8/29/20250.00 GBP
8/28/20250.00 GBP
8/27/20250.00 GBP
8/26/20250.00 GBP
8/22/20250.00 GBP
8/21/20250.00 GBP
8/20/20250.00 GBP
8/19/20250.00 GBP
8/18/20250.00 GBP
8/15/20250.00 GBP
8/14/20250.00 GBP
8/13/20250.00 GBP
8/12/20250.00 GBP
8/11/20250.00 GBP
Access this data via the Eulerpool API
Get Free API Key

Genedrive Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.94 M GBP
-5.26 M GBP
-5.97 M GBP
Jan 1, 2019
2.36 M GBP
-4.45 M GBP
-3.64 M GBP
Jan 1, 2020
1.06 M GBP
-5.64 M GBP
-19.42 M GBP
Jan 1, 2021
687,000.00 GBP
-5.48 M GBP
-691,000.00 GBP
Jan 1, 2022
49,000.00 GBP
-5.62 M GBP
-4.68 M GBP
Jan 1, 2023
55,000.00 GBP
-5.22 M GBP
-5.15 M GBP
Jan 1, 2024
501,000.00 GBP
-5.31 M GBP
-7.08 M GBP
Jan 1, 2025
954,000.00 GBP
-5.38 M GBP
-5.23 M GBP

Genedrive Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 10:35 PM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
5.005.005.005.005.004.005.002.001.002.001.00–––––
66.67––––-20.0025.00-60.00-50.00100.00-50.00–––––
60.0040.0020.0020.0020.0025.0020.0050.00100.0050.00100.00–––––
3.002.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
–––-1.00-2.00-4.00-5.00-5.00-5.00-4.00-5.00-5.00-5.00-5.00-5.00-5.00
–––-20.00-40.00-100.00-100.00-250.00-500.00-200.00-500.00–––––
–––-1.00-1.00-3.00-5.00-6.00-5.00-3.00-19.00–-4.00-5.00-7.00-5.00
–––––200.0066.6720.00-16.67-40.00533.33––25.0040.00-28.57
8.738.978.479.309.7610.0510.6718.6418.8726.2935.9074.45106.08117.71151.44562.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genedrive generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genedrive retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genedrive's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genedrive has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genedrive's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genedrive stock margins

The Genedrive margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genedrive. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genedrive.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
35.12 %
-271.62 %
-307.89 %
Jan 1, 2019
35.12 %
-188.36 %
-153.94 %
Jan 1, 2020
35.12 %
-532.58 %
-1,833.71 %
Jan 1, 2021
35.12 %
-797.96 %
-100.58 %
Jan 1, 2022
35.12 %
-11,459.18 %
-9,540.82 %
Jan 1, 2023
35.12 %
-9,498.18 %
-9,363.64 %
Jan 1, 2024
35.12 %
-1,060.28 %
-1,412.18 %
Jan 1, 2025
35.12 %
-563.94 %
-548.32 %

Genedrive Stock Revenue, EBIT, Earnings per Share

The Genedrive earnings per share therefore indicates how much revenue Genedrive has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.10 GBP
-0.28 GBP
-0.32 GBP
Jan 1, 2019
0.09 GBP
-0.17 GBP
-0.14 GBP
Jan 1, 2020
0.03 GBP
-0.16 GBP
-0.54 GBP
Jan 1, 2021
0.01 GBP
-0.07 GBP
-0.01 GBP
Jan 1, 2022
0.00 GBP
-0.05 GBP
-0.04 GBP
Jan 1, 2023
0.00 GBP
-0.04 GBP
-0.04 GBP
Jan 1, 2024
0.00 GBP
-0.04 GBP
-0.05 GBP
Jan 1, 2025
0.00 GBP
-0.01 GBP
-0.01 GBP

Genedrive business model & stock analysis

Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013. The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests. The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences. Some of Genedrive's key products include: - Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy. - Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes. - Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences. The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions. In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance. Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future.

Genedrive SWOT Analysis

Strengths

Genedrive PLC is a leading provider of molecular diagnostics solutions, possessing cutting-edge technology and expertise in the field.

The company has a diverse product portfolio, offering a range of diagnostic tests that are highly accurate, rapid, and easy to use.

Genedrive PLC has established strong partnerships and collaborations with renowned healthcare organizations, enhancing its market reach and credibility.

Weaknesses

Genedrive PLC heavily relies on its key products for revenue generation, which exposes the company to potential financial risks if these products face market challenges or fail to meet customer expectations.

The company's limited geographical presence and customer base in certain regions may hinder its growth potential.

Opportunities

The increasing demand for rapid and accurate molecular diagnostic tests presents a significant growth opportunity for Genedrive PLC.

Advancements in technology and increasing investments in healthcare infrastructure globally offer the company opportunities to expand its product offerings and enter new markets.

Genedrive PLC can leverage its expertise to develop diagnostic solutions for emerging diseases and public health emergencies, such as the COVID-19 pandemic, opening doors to collaborations with governments and international organizations.

Threats

Intense competition within the molecular diagnostics industry poses a threat to Genedrive PLC's market share and profitability.

Changes in regulatory policies and stringent approval processes for diagnostic tests can impact the company's ability to launch new products and achieve timely market access.

Global economic uncertainties and budget constraints in healthcare expenditure may limit Genedrive PLC's potential for revenue growth.

Genedrive Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genedrive historical P/E ratio, EBIT multiple, and P/S ratio

Genedrive annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genedrive shares outstanding

The number of shares of Genedrive was 562.85 M in 2025. This indicates how many shares Genedrive is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
18.87 M Stocks
Jan 1, 2019
26.29 M Stocks
Jan 1, 2020
35.90 M Stocks
Jan 1, 2021
74.45 M Stocks
Jan 1, 2022
106.08 M Stocks
Jan 1, 2023
117.71 M Stocks
Jan 1, 2024
151.44 M Stocks
Jan 1, 2025
562.85 M Stocks

Current Genedrive forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
0.87
Last Price
0.01
Currency
GBP
12M Return Potential
7,125.00 %
LTM Return
0 %

Genedrive Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
10/6/20090.01GBP-2.26 MGBP-2009 Q4
3/10/2009-0.08GBP-1.42 MGBP-2009 Q2

Genedrive shareholder structure

% Name
0.24632%
Rylands (Hugh John Joseph)
Rylands (Hugh John Joseph)
0.08037%
Octopus Investments Limited
Octopus Investments Limited
0.05330%
Burgess (Albert Edward)
Burgess (Albert Edward)
0.02564%
Potten (Stephen Christopher)
Potten (Stephen Christopher)
0.01935%
Potten (Edward James)
Potten (Edward James)
0.01935%
Potten (Christopher Stanislaus)
Potten (Christopher Stanislaus)

Genedrive Executives and Management Board

6 members · avg. age 58 · 0 % women

RS

Mr. Russell Shaw

Chief Financial Officer, Executive Director, Company Secretary · since 2022

214,911.00 GBP

Management

GM

Dr. Gino Miele (53)

Chief Executive Officer, Chief Scientific Officer, Executive Director · since 2023

173,202.00 GBP
PM

Mr. Paul Mcmanus

Financial PR and Investor Relations · since 2019

–

Board of Directors

IG

Dr. Ian Gilham (65)

Non-Executive Chairman of the Board · since 2014

65,000.00 GBP
TL

Mr. Tom Lindsay (67)

Non-Executive Director

35,000.00 GBP
CY

Mr. Christopher Yates (46)

Non-Executive Director

35,000.00 GBP

Genedrive Supply Chain

Genedrive Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Danaher
Supplier·Customer·Life Sciences Tools & Services·US
0.39
0.75
0.35
0.57
-0.14
-0.72
2
Inspiration Healthcare Gp
Customer·Health Care Equipment & Supplies·GB
-0.24
-0.54
0.43
0.36
0.53
-0.47
3
Sysmex
Customer·Health Care Equipment & Supplies·JP
0.83
0.90
-0.01
0.53
0.17
-0.34

Frequently asked questions about Genedrive

The business model of Genedrive PLC focuses on providing innovative and versatile molecular diagnostic solutions. Genedrive PLC develops and commercializes portable real-time polymerase chain reaction (PCR) platforms, primarily targeting infectious diseases. By combining rapid, accurate, and accessible testing with advanced molecular diagnostics, Genedrive PLC aims to address global health challenges. With its molecular diagnostics products, the company aims to improve patient outcomes by enabling healthcare professionals to make informed decisions quickly and effectively. Genedrive PLC's business model revolves around empowering diagnostic testing in diverse settings, ultimately contributing to better patient care and public health management.

Genedrive PLC is primarily active in the molecular diagnostics industry.

The main competitors of Genedrive PLC in the market include companies such as Roche Holding AG, Abbott Laboratories, QIAGEN N.V., and Thermo Fisher Scientific Inc. These companies operate in the same industry and offer similar products and services, competing with Genedrive in the field of molecular diagnostics and point-of-care testing. Genedrive PLC aims to differentiate itself through its innovative technology and product portfolio, but it faces competition from these established players in the market.

Genedrive PLC is a renowned biotech company founded in 2007. With headquarters in Manchester, United Kingdom, the company focuses on the development and commercialization of molecular diagnostic products meant to empower decentralized testing. Genedrive PLC has expertise in infectious diseases and pharmacogenetics, offering innovative solutions to improve patient outcomes globally. Over the years, Genedrive PLC has established itself as a leader in the field, collaborating with various organizations and expanding its product portfolio. The company's dedication to scientific advancements and commitment to improving healthcare make Genedrive PLC a reputable player in the biotech industry.

Some significant milestones achieved by Genedrive PLC include the successful development and commercialization of its innovative molecular diagnostics platform, which offers rapid and accurate diagnostic testing for infectious diseases. Genedrive PLC has also secured regulatory approvals for its products in key markets, allowing for global distribution. The company has formed strategic partnerships to expand its reach and enhance product development, such as collaborations with the Foundation for Innovation New Diagnostics and the US Department of Defense. Genedrive PLC has received numerous awards and recognition for its contributions to the field of molecular diagnostics, solidifying its position as a leader in the industry.

Genedrive PLC primarily operates in the United Kingdom, Europe, the Middle East, Africa, and the Asia-Pacific region. As a multinational company, Genedrive has a widespread presence, serving customers and collaborating with partners in various countries and regions around the world. With its innovative molecular diagnostics and point-of-care testing solutions, Genedrive has established a strong presence in these markets, delivering healthcare solutions and driving advancements in disease detection, monitoring, and management.

Genedrive PLC represents a values-driven and customer-centric corporate philosophy. The company is committed to delivering innovative molecular diagnostics solutions that address significant global healthcare challenges. Genedrive PLC focuses on providing efficient, cost-effective, and accurate diagnostic solutions for infectious diseases, pharmacogenetics, and oncology. With a strong emphasis on research and development, Genedrive PLC strives to constantly improve their product offerings and expand their global presence. The company's commitment to quality, integrity, and collaboration sets them apart and drives their mission to improve patient outcomes worldwide.

Analysts currently set an average price target of 86.70 GBP for the Genedrive stock (median: 86.70 GBP), implying +7,125.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Genedrive Analyst Price Targets 2026

9 analysts currently rate the Genedrive stock: 8 recommend buying, 1 holding and 0 selling.

Genedrive Analyst Price Targets 2026

Converted at the current exchange rate, the Genedrive share trades at 0.01 EUR (0.01 GBP).

The Genedrive share (GDR.L) is listed on 3 stock exchanges, including: Frankfurt (D6M.F), London (GDR.L), London (GDR.L).

Genedrive PLC is a rising British company specializing in diagnostics and test solutions for infectious diseases and Hepatitis C virus screening. The company's business concept is based on innovative technologies and products that enable rapid, accurate, and cost-effective identification and quantification of various pathogens. The company is divided into two main areas: Diagnostics and Clinical Applications. In the field of diagnostics, the company offers a wide range of molecular diagnostic tests for bacterial, viral, and parasitic infections, including tests for tuberculosis, malaria, and sexually transmitted diseases. The company's tests are based on the proprietary Genedrive platform, which delivers fast and precise results within 90 minutes. Clinical applications include pharmaceutical research and drug development, as well as personalized medicine. The company offers personalized tests for cancer diagnosis and treatment, as well as genetic tests for predicting disease risks and personalized drug development. Genedrive's products and services are aimed at laboratories, clinical research labs, as well as pharmaceutical and biotech companies worldwide. Another important business segment of Genedrive is Hepatitis C virus screening. The company has developed a hepatitis C virus screening device based on the Genedrive platform. This screening tool allows healthcare providers to diagnose and monitor hepatitis C patients faster and more effectively than conventional tests. Genedrive also offers a wide range of services, including consulting, training, and technology support for its customers. This service area is of great importance to the company as it helps to build long-term customer relationships and loyalty. Genedrive's business model is based on clear differentiation from its competitors through innovative technologies and products that enable the company to be successful in a competitive market. The company also benefits from a strong network of distribution partners in Europe, Asia, and Africa, who support the company in marketing and selling its products and services. Overall, Genedrive's business model is focused on innovation and high quality to meet customer needs. The company has a strong growth strategy that has allowed it to achieve rapid and profitable growth in recent years. With a strong focus on research and development, as well as service and support, Genedrive is well positioned to continue playing a strong role in the diagnostics and testing industry.

The revenue cannot currently be calculated for Genedrive.

The profit cannot currently be calculated for Genedrive.

The P/E ratio cannot be calculated for Genedrive at the moment.

The P/S cannot be calculated for Genedrive currently.

The Eulerpool Quality Score for Genedrive is 3/10.

The ISIN of Genedrive is GB00B1VKB244. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genedrive is A0ML2T. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genedrive is GDR.L. The ticker symbol is used to trade Genedrive shares on the stock exchange.

Genedrive paid dividends every year for the past 0 years.

Genedrive is assigned to the 'Health' sector.

The dividends of Genedrive are distributed in GBP.

All fundamentals and in-depth analysis of Genedrive

Our stock analysis for Genedrive stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genedrive. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genedrive Stock
Genedrive Revenue→
Genedrive Stock
Genedrive Net Income→
Genedrive Stock
Genedrive P/E→
Genedrive Stock
Genedrive P/S→
Genedrive Stock
Genedrive EBIT→
Genedrive Stock
Genedrive Dividend→
Genedrive Stock
Genedrive Directors Dealings→
Genedrive Stock
Genedrive Stocks→
Genedrive Stock
Genedrive Market capitalization→
Genedrive Stock
Genedrive Debt→
Genedrive Stock
Genedrive Liabilities→
Genedrive Stock
Genedrive Equity→
Genedrive Stock
Genedrive AAQS→
Genedrive Stock
Genedrive Employees→
Genedrive Stock
Genedrive ROE→
Genedrive Stock
Genedrive ROA→
Genedrive Stock
Genedrive ROCE→
Genedrive Stock
Genedrive News→
Genedrive Stock
Genedrive Analyst Price Targets→

Health Stocks

GeneDx HoldingsGeneBioTech CoGenelinkGene One Life ScienceGeneluxGencurixGenematrixGemPharmatech CoGenenta Science SpA ADRGelteqGeneral BiologicalsGelstatAll Stocks A–Z →